Plasma biomarkers for Alzheimer’s disease: a field-test in a memory clinic

BACKGROUND: The key Alzheimer’s disease (AD) biomarkers are traditionally measured with techniques/exams that are either expensive (amyloid-positron emission tomography (PET) and tau-PET), invasive (cerebrospinal fluid Aβ(42) and p-tau(181)), or poorly specific (atrophy on MRI and hypometabolism on...

Descripción completa

Detalles Bibliográficos
Autores principales: Altomare, Daniele, Stampacchia, Sara, Ribaldi, Federica, Tomczyk, Szymon, Chevalier, Claire, Poulain, Géraldine, Asadi, Saina, Bancila, Bianca, Marizzoni, Moira, Martins, Marta, Lathuiliere, Aurelien, Scheffler, Max, Ashton, Nicholas J, Zetterberg, Henrik, Blennow, Kaj, Kern, Ilse, Frias, Miguel, Garibotto, Valentina, Frisoni, Giovanni B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Neurodegeneration
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10314086/
https://www.ncbi.nlm.nih.gov/pubmed/37012066
http://dx.doi.org/10.1136/jnnp-2022-330619

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10314086/
https://www.ncbi.nlm.nih.gov/pubmed/37012066
http://dx.doi.org/10.1136/jnnp-2022-330619

Ejemplares similares